On 10 November 2026, the Office of the Drugs Controller General (India) issued three official letters to all State and Union Territory licensing authorities. Each letter recommends a change to the prescribing information leaflet (PIL), and asks those authorities to direct manufacturers to mention a named adverse drug reaction in the package insert or promotional literature. The three medicines, and the reactions named, are:

  • Furosemide: dermatitis lichenoid
  • Phenytoin: acute generalised exanthematosus pustulosis (AGEP)
  • Lithium carbonate: drug reaction with eosinophilia and systemic symptoms syndrome (DRESS)

CDSCO lists all three letters on its Adverse Drug Reaction related Notifications page, with the release date 10 November 2026. We opened the official PDFs on 16 November 2026. This page is the start of a record of CDSCO prescribing leaflet safety updates for clinic prescribers. It reports what those letters say, and what they do not say. It is not clinical advice, and it does not tell you whether to start, continue or stop any medicine.

Information as of 16 November 2026, Asia/Calcutta. This is a general guide, not medical or legal advice. The sections marked "our reading" are not an official CDSCO checklist. Recheck the current letter, and the current package insert, before you change clinic practice.

The short answer

  • Letters to licensing authorities, not a ban. Each document is a letter from the Drugs Controller General (India) to all State and Union Territory licensing authorities. It requests them to direct manufacturers under their jurisdiction to mention the named reaction in the package insert or promotional literature, and to intimate the action taken to that office.
  • The official wording is specific. The furosemide letter says "Dermatitis Lichenoid", not a broader word such as dermatitis alone. The phenytoin letter says "Acute Generalised Exanthematosus Pustulosis (AGEP)". The lithium letter says "Drug Reaction with Eosinophilia and Systemic symptoms Syndrome (DRESS)" for lithium carbonate formulations.
  • The scientific review dates and the letter date are both in the documents. Each letter cites a PvPI Signal Review Panel meeting on 29 November 2016, and a Subject Expert Committee meeting in March or April 2017. The letters themselves are dated 10 November 2026. We report both. We do not explain the gap, because the letters do not.
  • What we did not find. We did not find, in these letters, a direction to doctors to stop prescribing the medicines, a new dose, a new prescription format, or a start date by which a clinic must change its pad.
  • What Medabha does not do. It does not flag these three reactions, and it does not keep a copy of the package insert for you.

What the 10 November letters actually are

Each letter is issued on the letterhead of the Government of India, Directorate General of Health Services, Central Drugs Standard Control Organization, Office of the Drugs Controller General (India), Post Marketing Drugs Safety Monitoring Division, FDA Bhawan, Kotla Road, New Delhi 110002. Each is dated 10 November 2026. Each uses the same file number, PSUR-13011(14)/1/2025-eoffice. Each is addressed to all State and Union Territory licensing authorities, and is signed by Dr Rajeev Singh Raghuvanshi, Drugs Controller General (India). Copies go to CDSCO zonal and sub-zonal offices and CDSCO headquarters, to the Joint Secretary (Regulation) at Nirman Bhawan, and to PvPI at the Indian Pharmacopoeia Commission, Ghaziabad.

The subject line of each letter is a recommendation for a change in prescribing information leaflets (PILs). The request at the end is the same in substance: the licensing authority is asked to direct the manufacturers of the relevant formulations under its jurisdiction to mention the named reaction as an adverse drug reaction in the package insert or promotional literature of the drug, and to intimate the action taken to the office.

CDSCO publishes the PDFs through its Adverse Drug Reaction related Notifications page. On 16 November 2026 that page listed them as:

  1. Lithium Carbonate, Drug Reaction with Eosinophilia and Systemic symptoms Syndrome (DRESS), 2026-Nov-10
  2. Phenytoin, Acute Generalised Exanthematosus Pustulosis (AGEP), 2026-Nov-10
  3. Furosemide, Dermatitis Lichenoid, 2026-Nov-10

They were not, on that date, on the Latest Circulars page, whose first item was still the 21 September 2026 circular on painkillers and antibiotics, and they were not in the rows we read on the main Circulars list. A secondary report on DrugsControl, dated 13 November 2026, described the documents as circulars and summarised them behind a login. We follow the official letters and the official listing, and we call them letters.

This is a different kind of document from CDSCO's September 2026 circular on NSAIDs and antibiotics, which is addressed to the public, healthcare professionals, pharmacists, hospitals and state drug controllers, and which restates how those medicines should be prescribed and sold. The 10 November letters are about what manufacturers should add to labelled information.

The three updates, in the letters' own terms

We opened each official PDF. The wording below follows those letters. We do not add clinical descriptions of the reactions, and we do not add doses.

Furosemide, dermatitis lichenoid. The letter's subject is "Furosemide related Dermatitis Lichenoid - Recommendations for the change in Prescribing Information Leaflets (PILs)". It says a safety signal of dermatitis lichenoid associated with furosemide was identified after evaluation of Periodic Safety Update Report (PSUR) data of furosemide formulations by CDSCO, and was examined with Individual Case Safety Reports (ICSRs) in the PvPI database. The Signal Review Panel recommended that CDSCO take measures to incorporate "Dermatitis Lichenoid" as an adverse drug reaction in the PIL of furosemide-based medical products marketed in the country. The Subject Expert Committee on reproductive and urology reviewed that recommendation at CDSCO headquarters, New Delhi, on 20 April 2017, and recommended that CDSCO request State Drugs Controllers to direct manufacturers to incorporate "Dermatitis Lichenoid associated with Furosemide as an Adverse Drug Reaction (ADR) in the corresponding Prescribing Information Leaflet (PIL) of the drug." The office then asks licensing authorities to direct manufacturers of furosemide formulations to mention "Dermatitis Lichenoid" as an adverse drug reaction in the package insert or promotional literature.

Phenytoin, AGEP. The letter's subject is "Phenytoin related Drug Reaction with Acute Generalised Exanthematosus Pustulosis (AGEP) - Recommendations for the change in Prescribing Information Leaflets (PILs)". The same PSUR and ICSR path is described, and the same Signal Review Panel date, 29 November 2016. The Subject Expert Committee on Neurology and Psychiatry reviewed the recommendation at CDSCO headquarters on 17 March 2017, and recommended that manufacturers be directed to incorporate "Acute Generalised Exanthematosus Pustulosis (AGEP) associated with Phenytoin as an Adverse Drug Reaction (ADR) in the corresponding Prescribing Information Leaflet (PIL) of the drug." The office asks licensing authorities to direct manufacturers of phenytoin formulations to mention "Acute Generalised Exanthematosus Pustulosis (AGEP)" as an adverse drug reaction in the package insert or promotional literature.

Lithium carbonate, DRESS. The letter's subject is "Lithium Carbonate related Drug Reaction with Eosinophilia and Systemic symptoms Syndrome (DRESS) - Recommendations for the change in Prescribing Information Leaflets (PILs)". Again the signal is described as coming from PSUR data and from ICSRs in the PvPI database, discussed in the 9th Signal Review Panel on 29 November 2016. The Subject Expert Committee on Neurology and Psychiatry reviewed it on 17 March 2017, and recommended that manufacturers be directed to incorporate "Drug Reaction with Eosinophilia and Systemic symptoms Syndrome (DRESS) associated with Lithium Carbonate as an Adverse Drug Reaction (ADR) in the corresponding Prescribing Information Leaflet (PIL) of the drug." The office asks licensing authorities to direct manufacturers of lithium carbonate formulations to mention that reaction in the package insert or promotional literature.

The official letters use the spelling "Exanthematosus" and "Systemic symptoms Syndrome". We keep that spelling when we quote them, rather than substituting a more common spelling.

The 2016 and 2017 dates, and the 2026 letters

Each letter is dated 10 November 2026 and, in the same text, dates the Signal Review Panel meeting to 29 November 2016 and the Subject Expert Committee meetings to March or April 2017. That is a fact in the documents, not an inference.

Our reading, only: the letters present a safety-signal review that took place in 2016 and 2017, and a direction to State and Union Territory licensing authorities dated 10 November 2026. We have not seen, in these three PDFs, a sentence that explains the time between those meetings and the 2026 letters. We do not fill that gap. A legal read should look at this point before the page is promoted.

The letters also do not, in the text we opened, give manufacturers a number of days in which the package insert must be changed, or tell doctors when they should expect to see the new text on a pack. Action taken is to be intimated to the office. What happens next is for the licensing authorities and the manufacturers.

What this means for a clinic prescriber (our reading)

This list is our reading for a clinic or a nursing-home OPD. It is not an official CDSCO checklist, and it is not clinical advice.

  1. These letters are about labelled information. They ask that a named reaction be mentioned in the prescribing information leaflet, the package insert or the promotional literature. They are not, in the words we opened, a direction to you to change a dose or to stop a medicine.
  2. If you prescribe one of these medicines, the official text to watch is the current package insert, once it has been updated, together with the letter itself. This page is a reading aid, not a substitute for that insert.
  3. Write what the patient already needs on the record: the medicine, the dose, the frequency, the duration, and the reason for the visit. That habit is the same one described in our prescription software guides. These letters do not add a new mandatory field for these three drugs.
  4. Do not treat a secondary news summary as the official wording. The DrugsControl report we opened on 16 November 2026 used "circulars" and, in its headline, "Furosemide-Linked Dermatitis". The official furosemide letter says "Dermatitis Lichenoid". Where a report and the PDF differ, follow the PDF.
  5. If a later official letter or a revised insert differs from this page, follow that letter or insert. This page should then be updated from the official document.

What these letters do not say

The table is a reading aid. Every "stated" line is taken from the three official PDFs or from the CDSCO listing page. Every "not found" line means we did not find it in those sources on 16 November 2026.

Topic Stated in these letters or on the official listing Not found in these sources
Who is addressed All State and Union Territory licensing authorities, who are asked to direct manufacturers A direction addressed to individual clinic prescribers to change their practice
What must be mentioned Dermatitis lichenoid (furosemide); AGEP (phenytoin); DRESS (lithium carbonate), in the PIL, package insert or promotional literature A ban, a withdrawal, a restricted-prescriber list, or a new dose
Review history PSUR and PvPI ICSR review; 9th Signal Review Panel, 29 November 2016; SEC meetings in March and April 2017; letters dated 10 November 2026 An explanation, in these letters, of the time between the 2017 meetings and the 2026 direction; a deadline for the insert to change
Clinic records Nothing in these letters creates a new prescription-pad layout A new form, register or reporting duty for a private OPD

How this page will be updated

CDSCO's Adverse Drug Reaction related Notifications page already lists other 2026 letters, including entries dated 21 September 2026 and earlier, which we have not opened for this page. We do not summarise a letter we have not read.

Our reading: it is better to keep one page for CDSCO prescribing leaflet safety updates, and to add a later official letter here after we have opened it, than to start a new post for each batch. The title of this page does not name only the three medicines, so a later letter can be added as a dated section without changing the heading. Until such a letter is opened and added, this page covers only the three letters dated 10 November 2026.

Where Medabha fits, and where it does not

Prescription software in Medabha can print the medicine line you type, including dose, frequency and duration, on a signed visit prescription. It flags a short list of drug-pair and condition clashes. That list does not include dermatitis lichenoid with furosemide, AGEP with phenytoin, or DRESS with lithium carbonate. The product does not store the official package insert, and it does not tell you when a manufacturer has updated one.

If a warning from the short list is showing, signing stops until you tick that you have reviewed it. You can still sign. The decision stays with you. The absence of a warning for these three reactions is not a finding that the reactions are unimportant. It means only that they are not in the current check.

Sources

  • Central Drugs Standard Control Organization, Adverse Drug Reaction related Notifications page, opened 16 November 2026, listing Lithium Carbonate (DRESS), Phenytoin (AGEP) and Furosemide (Dermatitis Lichenoid), each dated 2026-Nov-10, official listing.
  • Office of the Drugs Controller General (India), letter dated 10 November 2026, file number PSUR-13011(14)/1/2025-eoffice, "Furosemide related Dermatitis Lichenoid - Recommendations for the change in Prescribing Information Leaflets (PILs)", official PDF opened 16 November 2026 from cdsco.gov.in.
  • Office of the Drugs Controller General (India), letter dated 10 November 2026, same file number, "Phenytoin related Drug Reaction with Acute Generalised Exanthematosus Pustulosis (AGEP) - Recommendations for the change in Prescribing Information Leaflets (PILs)", official PDF opened 16 November 2026 from cdsco.gov.in.
  • Office of the Drugs Controller General (India), letter dated 10 November 2026, same file number, "Lithium Carbonate related Drug Reaction with Eosinophilia and Systemic symptoms Syndrome (DRESS) - Recommendations for the change in Prescribing Information Leaflets (PILs)", official PDF opened 16 November 2026 from cdsco.gov.in. The official filename includes a space before .pdf.
  • DrugsControl Media Services, "CDSCO Directs States to Update PILs for Furosemide-Linked Dermatitis, Phenytoin-Linked AGEP and Lithium Carbonate-Linked DRESS," 13 November 2026, news item. Used only as a secondary report. The full body was behind a login when we opened it. Where it differs from the official letters, we follow the letters.

What we could not confirm

  • A direction in these letters that a clinic prescriber must stop, restrict or re-dose furosemide, phenytoin or lithium carbonate.
  • A deadline by which manufacturers must change the package insert, or a date by which a doctor should expect to see the new text on a pack.
  • An official explanation, in these letters, of the time between the 2016 and 2017 review meetings and the 10 November 2026 direction.
  • The full text of the DrugsControl article, which was truncated and behind a login on 16 November 2026.
  • The contents of other 2026 letters on the same CDSCO Adverse Drug Reaction related Notifications page, which we have not opened for this page.

This is a general guide, not medical or legal advice. Information as of 16 November 2026, Asia/Calcutta. If a later official letter or a revised package insert differs from the documents cited here, follow that letter or insert.

Frequently asked questions

Do the 10 November 2026 letters tell me to stop prescribing furosemide, phenytoin or lithium?

No. The three letters we opened, each dated 10 November 2026 and signed by the Drugs Controller General (India), are addressed to all State and Union Territory licensing authorities. They request those authorities to direct manufacturers, under their jurisdiction, to mention a named adverse drug reaction in the package insert or promotional literature of the relevant formulations: dermatitis lichenoid for furosemide, acute generalised exanthematosus pustulosis (AGEP) for phenytoin, and drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) for lithium carbonate. The letters do not, in the text we opened, withdraw the medicines, restrict who may prescribe them, or give a new dose. This page is a general guide, not medical or legal advice, and it does not tell you whether to start, continue or stop a medicine for any patient.

Are these CDSCO circulars, and where are they published?

CDSCO lists all three documents on its Adverse Drug Reaction related Notifications page, each with the release date 10 November 2026. They are official letters from the Office of the Drugs Controller General (India), Post Marketing Drugs Safety Monitoring Division, on file number PSUR-13011(14)/1/2025-eoffice, addressed to all State and Union Territory licensing authorities. They were not, when we checked on 16 November 2026, listed on CDSCO's Latest Circulars page or on the main Circulars list. A secondary news report described them as circulars. We follow the documents themselves, and the official listing, and we call them letters. This is a general guide, not legal advice.

Why do the letters, dated 10 November 2026, cite review meetings from 2016 and 2017?

Because that is what the letters themselves say. Each letter says a safety signal was identified after evaluation of Periodic Safety Update Report (PSUR) data by CDSCO, examined with Individual Case Safety Reports in the Pharmacovigilance Programme of India (PvPI) database, and discussed in the 9th Signal Review Panel of PvPI (NCC-PvPI) held on 29 November 2016. The recommendations were later reviewed by a Subject Expert Committee at CDSCO headquarters in 2017: the SEC on Neurology and Psychiatry on 17 March 2017 for lithium carbonate and for phenytoin, and the SEC on reproductive and urology on 20 April 2017 for furosemide. The office letters directing State and Union Territory licensing authorities are dated 10 November 2026. We report both sets of dates. We have not seen, in these letters, an explanation of the time between the committee meetings and the 2026 direction, and we do not invent one. This is a general guide, not legal advice.

Does Medabha warn me about dermatitis lichenoid, AGEP or DRESS for these medicines?

No. Medabha's prescription check is a short list of drug-pair and condition clashes. It is not a complete interaction database, and it does not include a warning that furosemide is associated with dermatitis lichenoid, that phenytoin is associated with AGEP, or that lithium carbonate is associated with DRESS. Those reactions are what the 10 November 2026 letters ask manufacturers to mention in the package insert or promotional literature. If you prescribe these medicines, the official source for the labelled text is the current package insert, once manufacturers have updated it, and the letters themselves. The decision to prescribe stays with you.

Try Medabha in your own clinic

AI medical scribe, WhatsApp prescriptions, specialty charts and a built-in clinic website, set up in minutes.

Start 14-day free trial Prefer a walkthrough? Book a demo

No card needed.

This article is general information about clinic software and documentation workflows, not medical, legal or regulatory advice. Check current requirements with the relevant authority before making compliance decisions.